Here, we report two cases of severe rhabdomyolysis, regarding patients with metastatic renal cell cancer (RCC) receiving treatment with sunitinib.
The first case was a 74-year-old woman with lung and bone metastases from RCC diagnosed in 2007. Neither comorbities were present nor concomitant treatments were given. Karnofsky performance status (KPS) was 100. Cardiac, hepatic, bone marrow and thyroid function were within the normal range. Serum creatinine was normal. The left ventricular ejection fraction (LVEF) at baseline was 65%. The patient started first-line treatment with sunitinib at the dose of 37.5 mg/day on a schedule of 4/2. No major toxic effects were registered until the day 26 of the third course when the patient presented severe weakness, asthenia, oliguria with renal failure along with marked elevation of transaminases, lactate dehydrogenase (LDH), creatine-phosphokinase (CPK) and myoglobin (Table 1) . No alteration of the thyroid function was present. No sign of cardiac damage was observed on electrocardiogram, while the echocardiogram showed a marked decrease of LVEF to 28%. Acute myocardial infarction was ruled out as a cause of the elevated CPK levels, and a diagnosis of rhabdomyolysis was established. After 3 days, a right pleural effusion, anuria and hypotension together with a dramatic rise in the levels of myoglobin and CPK were detected. Then, the patient presented coma and died few hours later.
The second case was a 77-year-old man with multiple lung metastases from RCC diagnosed in 2004. At start of treatment with sunitinib (50 mg/day, schedule 4/2), his KPS was 100% and no alterations in the cardiologic and hematologic tests were present. Serum creatinine was within normal range. At fourth cycle, an asymptomatic hypothyroidism was detected. Thyroid replacement treatment was started and sunitinib therapy continued. At the end of the fifth cycle, the patient presented generalized impairment in carrying out normal daily activities (KPS of 40); marked asthenia; jaundice; thrombocytopenia and increased values of creatinine, transaminases and CPK. Bilateral pleural effusion and ascites were detected, as well as imaging suggestive of cirrhotic liver. On day 3, the patient developed anuria; severe dyspnea and an increase of transaminases; bilirubin, myoglobin, CPK and LDH (Table 1) . A computed tomography scan suggested an acute heart failure together with ground glass areas in lungs, bilateral pleural effusion and liver stasis. The echocardiogram showed an LVEF of 28% with diffuse hypokinesia. The patient underwent hemodialysis until spontaneous diuresis and normalization of renal function tests was attained. During the following weeks, the patient recovered and all laboratory tests normalized. An improvement of cardiac function was seen (LVEF: 34%) and 6 months later, the patient is alive with a stable disease and an LVEF of 50%.
These two cases are suggestive of rhabdomyolysis secondary to sunitinib therapy. Cases of rhabdomyolysis had already been described [1] [2] [3] [4] [5] . Acute kidney failure is the most serious complication of rhabdomyolysis. In our cases, the severity and the outcome may be related both to the multiorgan failure and to the fact that both patients were nephrectomized. Sunitinib is a standard of care for patients affected with mRCC with good or intermediate prognosis and is considered as a safe and effective treatment, although cardiovascular events have received increased attention. It has been suggested that the cardiotoxicity may be the result of a direct effect of this drug on the myocytes. The observation of two cases of acute rhabdomyolysis with multiorgan failure suggests that the damage may be directed to all striated muscles, including myocytes, and that the cardiotoxicity could be an epiphenomenon of a wider effect. This could partly explain the 
